Entia Biosciences, Inc. Names Chief Executive Officer to Manage Growth of Consumer Health Products and To Launch New Medical Food Brands

New Business Strategy to Capitalize on Unique, Innovative and Proprietary Entia Products

SHERWOOD, OR / ACCESSWIRE / August 13, 2015 / Entia Biosciences, Inc. (ERGO), today announced that Carl J. Johnson has joined the Company to serve as its President and Chief Executive Officer and member of the Board of Directors. Mr. Johnson has more than 40 years of experience in managing the introduction and marketing of new health-related products as well as executive leadership roles where he last served as President, CEO and Board Member of Matrixx Initiatives, Inc. from 2001 until 2008. Mr. Johnson will be an important addition to the Entia's growth plans and his prior experience will provide focus and commercial discipline to future efforts.

Founder, current CEO and Board Chairman, Marvin S. Hausman MD, will remain Chairman and fill the new and important position of Chief Science and Technology Officer for Entia. This period is a critical time for the Company as it launches its proprietary ErgoD2(R) medical foods for the therapeutic benefit of several chronic diseases. Entia is entering a new phase of commercial activity preparing for the launch of the unique, innovative and proprietary ErgoD2(R) medical food products. Additionally, Entia Biosciences, Inc. is encouraged by the early success of its GROH(R) cosmeceutical product line and is evaluating more aggressive marketing support for these products. This division of responsibilities is an expected apportionment of professional responsibilities as Entia not only expands into a whole new medical industry but also requires greater management of the food studies and product launches. From the many preliminary preclinical and clinical study results observed to date, Entia's all-natural, organic, gluten-free mushroom-based food, ErgoD2(R)-discovered by Hausman, is demonstrating medical potency.

By way of background, Mr. Johnson helped lead Matrixx Initiatives, Inc. and its Zicam(R) brand of cough and cold products grow from $10 million to over $100 million in revenue. He presently serves as a member of the Board of Directors of Prestige Brands Holdings, Inc. (NYSE-PBH). He also served as a Board Member of Matrixx Initiatives from February 2011 to February 2014 and as Interim CEO when the business was acquired by HIG Capital. Previously from 1993 to 2001, Mr. Johnson was Vice President of Commercial Development with Perrigo Company where he was responsible for the procurement of new products and technologies and contract manufacturing services with emphasis on Abbreviated New Drug Applications (ANDA) products. From 1972 through 1989, Mr. Johnson worked at Johnson & Johnson (NYSE-JNJ) where he held a number of high-level marketing and sales positions in JNJ's Baby Product's Company. He also served as Vice President of Sales & Marketing for the introduction of Acuvue(R) disposable contact lens products.

According to a statement by Dr. Hausman, "Entia has come a considerable ways from discovery of ErgoD2(R) to introducing our nutraceutical line, creating and sponsoring our own, premium brand cosmeceutical products-GROH(R) and now, developing and launching our own medical food products aimed at actually providing therapeutic benefit for the treatment of certain diseases. The entry of Mr. Johnson should change the entire presence, brand and market awareness of the Company. Mr. Johnson is an experienced executive with a proven track record to help us make these important transitions. His experience in creating, synthesizing, launching and developing 'top-of-mind awareness' of health products in the past is the exact combination of talents we need to further Entia Biosciences, Inc. position and reach across a broad collection of markets. Already, Carl has greatly helped Entia focus our internal attention into the products you will see us pursue as well as help me address the capital markets to better fund the cash requirements to make this plan come to fruition. We expect Carl's contributions will accelerate the growth of our existing nutraceutical and cosmeceutical products as well as help with the launch of our medical food line resulting in broader penetration and increased sales of our ErgoD2(R)-based products."

Carl Johnson commented, "I am very excited to join Entia because of the Company's prospects in all three market areas. Regarding the medical food business, I believe we are at the very beginning of what will become a major new health/therapeutic category. The growth of this new category is driven by the high cost of developing new ethical drugs, the lengthy time-to-market new drugs require, society's increasing demand for organic and whole-food therapies as well as the emerging shift in retail drug merchandizing to provide point-of-care assistance in their outlets. I am pleased to lead Entia as it ventures from its current product base to the medical food opportunity."

About Entia Biosciences, Inc.

Entia is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and Nutrigenomics. The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture. Its first pure, 100% organic substance is derived from "energized" mushrooms that are biologically high in two beneficial components-- L-Ergothioneine, a naturally occurring amino acid and master antioxidant as well as vitamin D, an important vitamin that supports one's immune system. ErgoD2(R), our name for this powerful combination, is the foundation for our nutraceutical and beauty product lines and will be evaluated in clinical trials as a medical food. www.entiabio.com

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2014 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

CONTACT:

Marvin S. Hausman, M.D.
Chief Science Officer
Entia Biosciences, Inc.
13565 SW Tualatin-Sherwood Rd.
Sherwood, OR 97140
(503) 334-3575
info@entiabio.com

SOURCE: Entia Biosciences, Inc.